Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-07-14
2009-08-18
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S266200, C514S266300, C514S266400, C544S284000, C544S287000, C544S293000
Reexamination Certificate
active
07576074
ABSTRACT:
The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.
REFERENCES:
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5962458 (1999-10-01), Lohmann et al.
patent: 6184225 (2001-02-01), Thomas et al.
patent: 2002/0049197 (2002-04-01), Himmelsbach et al.
patent: WO97/22596 (1997-06-01), None
patent: WO 98/13354 (1998-04-01), None
patent: WO 00/20402 (2000-04-01), None
patent: WO 01/21594 (2001-03-01), None
patent: WO 01/21595 (2001-03-01), None
patent: WO 01/21596 (2001-03-01), None
patent: WO 01/32651 (2001-05-01), None
patent: WO 01/74360 (2001-10-01), None
patent: WO 01/77085 (2001-10-01), None
patent: WO 02/18372 (2002-03-01), None
patent: WO 03/000188 (2003-01-01), None
patent: WO03082831 (2003-10-01), None
Bridges, et. al., Journal of Medicinal Chemistry (1996), 39(1), 267-76.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Vippagunta et. al. Advanced Drug Delivery Reviews 48 (2001) 3-26.
Bonasera et al Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nuclear Medicine and Biology (2001), 28(4), 359-374.
Christensen JG et al. Proc Amer Assoc Cancer Res [94thannual Meeting Amer Assoc Cancer Res- AACR (Jul. 11-14, Washington DC) 2003] 2003, 44: Abstract 4963.
MAulik G. et al Proc Amer Assoc Cancer Res [94th annual Meeting Amer Assoc Cancer Res- AACR (Jul. 11-14, Washington, DC) 2003] 2003, 44: Abstract 6200.
Sattler et al. Proc Amer Assoc Cancer Res [94th annual Meeting Amer Assoc Cancer Res- AACR (Jul. 11-14, Washington, DC) 2003] 2003, 44: Abstract 1005.
Hennequin, L.F. et al., “Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors”, Journal of Medicinal Chemistry, American Chemical Society, vol. 42, 1999, pp. 5369-5389.
Supplementary European Search Report, European Application No. EP03764599.
Anand Neel K.
Bussenius Joerg
Kennedy Abigail R.
Kim Angie I.
Peto Csaba J.
McDonnell Boehnen & Hulbert & Berghoff LLP
Murray Jeffrey H
Rice Janice V.
Wilson James O
LandOfFree
Receptor-type kinase modulators and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Receptor-type kinase modulators and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Receptor-type kinase modulators and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4105865